62 related articles for article (PubMed ID: 1301581)
1. Bladder cancer recurrence and its association with cytochrome P-450IID6 activity.
Persad RA; Fleming CM; Wilkinson GR; Smith PJ; Branch RA
Prog Clin Biol Res; 1992; 378():19-27. PubMed ID: 1301581
[No Abstract] [Full Text] [Related]
2. [Metabolic polymorphisms and the cancer risk: the evaluation of epidemiological studies].
Vineis P; Landi MT; Caporaso N
Med Lav; 1992; 83(6):557-75. PubMed ID: 1296137
[TBL] [Abstract][Full Text] [Related]
3. The effect of tobacco on lung cancer risk depends on CYP2D6 activity.
Bouchardy C; Benhamou S; Dayer P
Cancer Res; 1996 Jan; 56(2):251-3. PubMed ID: 8542575
[TBL] [Abstract][Full Text] [Related]
4. Study design and genetic susceptibility factors in the risk assessment of chemical carcinogens.
Caporaso N
Ann Ist Super Sanita; 1991; 27(4):621-30. PubMed ID: 1820735
[TBL] [Abstract][Full Text] [Related]
5. [Heterologous expression of functionally active human cytochrome P-450. I. Synthesis of cytochrome P-450IID6 by transformed Saccharomyces cerevisiae cells].
Krynetskiĭ EIu; Kovaleva IE; El'darov MA; Luzikov VN
Mol Biol (Mosk); 1993; 27(5):1094-9. PubMed ID: 8246932
[TBL] [Abstract][Full Text] [Related]
6. Polymorphism of human CYP2D genes involved in drug metabolism: possible relationship to individual cancer risk.
Nebert DW
Cancer Cells; 1991 Mar; 3(3):93-6. PubMed ID: 2054261
[No Abstract] [Full Text] [Related]
7. Expression of cyclooxygenase-2 in primary superficial bladder cancer tissue may predict risk of its recurrence after complete transurethral resection.
Okajima E; Uemura H; Ohnishi S; Tanaka M; Ohta M; Tani M; Fujimoto K; Ozono S; Okajima E; Hirao Y
Aktuelle Urol; 2003 Jul; 34(4):256-8. PubMed ID: 14566678
[TBL] [Abstract][Full Text] [Related]
8. Clinically significant cytochrome P-450 drug interactions--a comment.
Ford NF; Sonnichsen DS
Pharmacotherapy; 1998; 18(4):890-1; discussion 892-3. PubMed ID: 9692671
[No Abstract] [Full Text] [Related]
9. The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers.
Tada Y; Wada M; Taguchi K; Mochida Y; Kinugawa N; Tsuneyoshi M; Naito S; Kuwano M
Cancer Res; 2002 Jul; 62(14):4048-53. PubMed ID: 12124340
[TBL] [Abstract][Full Text] [Related]
10. [Biotransformation of sparteine in the Cuna American Indians of Panama].
Arias TD; Jorge L; Lee D; Guerrero de Solís N; Escobar J; Barrantes R; Inaba T
Rev Med Panama; 1986 Sep; 11(3):199-209. PubMed ID: 3468564
[No Abstract] [Full Text] [Related]
11. Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancer.
Jancke G; Damm O; Rosell J; Jahnson S
Scand J Urol Nephrol; 2008; 42(5):417-21. PubMed ID: 18609266
[TBL] [Abstract][Full Text] [Related]
12. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
[TBL] [Abstract][Full Text] [Related]
13. Computer prediction and experimental validation of cytochrome P4502D6-dependent oxidation of GBR 12909.
de Groot MJ; Bijloo GJ; Hansen KT; Vermeulen NP
Drug Metab Dispos; 1995 Jun; 23(6):667-9. PubMed ID: 7587951
[No Abstract] [Full Text] [Related]
14. Gene-environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism.
Landi MT; Ceroni M; Martignoni E; Bertazzi PA; Caporaso NE; Nappi G
Adv Neurol; 1996; 69():61-72. PubMed ID: 8615186
[No Abstract] [Full Text] [Related]
15. The ability to 4-hydroxylate debrisoquine is related to recurrence of bladder cancer.
Fleming CM; Kaisary A; Wilkinson GR; Smith P; Branch RA
Pharmacogenetics; 1992 Jun; 2(3):128-34. PubMed ID: 1306112
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the Na,K-ATPase alpha- and beta-subunit expression profiles of bladder cancer using tissue microarrays.
Espineda C; Seligson DB; James Ball W; Rao J; Palotie A; Horvath S; Huang Y; Shi T; Rajasekaran AK
Cancer; 2003 Apr; 97(8):1859-68. PubMed ID: 12673711
[TBL] [Abstract][Full Text] [Related]
17. CYP1A2 activity as a risk factor for bladder cancer.
Lee SW; Jang IJ; Shin SG; Lee KH; Yim DS; Kim SW; Oh SJ; Lee SH
J Korean Med Sci; 1994 Dec; 9(6):482-9. PubMed ID: 7786445
[TBL] [Abstract][Full Text] [Related]
18. Identification of the primary gene defect at the cytochrome P450 CYP2D locus.
Gough AC; Miles JS; Spurr NK; Moss JE; Gaedigk A; Eichelbaum M; Wolf CR
Nature; 1990 Oct; 347(6295):773-6. PubMed ID: 1978251
[TBL] [Abstract][Full Text] [Related]
19. The procarcinogen hypothesis for bladder cancer: activities of individual drug metabolizing enzymes as risk factors.
Branch RA; Chern HD; Adedoyin A; Romkes-Sparks M; Lesnick TG; Persad R; Wilkinson GR; Fleming CM; Dickinson AJ; Sibley G
Pharmacogenetics; 1995; 5 Spec No():S97-102. PubMed ID: 7581498
[TBL] [Abstract][Full Text] [Related]
20. Genetic predisposition to Balkan endemic nephropathy: ability to hydroxylate debrisoquine as a host risk factor.
Nikolov IG; Chernozemsky IN; Idle JR
IARC Sci Publ; 1991; (115):289-96. PubMed ID: 1820343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
